相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer
Phonphimon Wongthida et al.
CANCER RESEARCH (2010)
T-Cell Receptor Gene-Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy
Matthias Leisegang et al.
CLINICAL CANCER RESEARCH (2010)
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma
F. Galivo et al.
GENE THERAPY (2010)
Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer
P. Castelo-Branco et al.
GENE THERAPY (2010)
Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-beta for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy
Vassiliki Saloura et al.
HUMAN GENE THERAPY (2010)
Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus
Feorillo Galivo et al.
HUMAN GENE THERAPY (2010)
Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective
Robert E. Hawkins et al.
HUMAN GENE THERAPY (2010)
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Byram W. Bridle et al.
MOLECULAR THERAPY (2010)
Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
Fabrice Le Boeuf et al.
MOLECULAR THERAPY (2010)
Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy
Yu-Qian Zhang et al.
MOLECULAR THERAPY (2010)
Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus
Robin J. Prestwich et al.
JOURNAL OF IMMUNOLOGY (2009)
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
Robin J. Prestwich et al.
CLINICAL CANCER RESEARCH (2008)
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
Franz O. Smith et al.
CLINICAL CANCER RESEARCH (2008)
A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus
Ju-mei Zhao et al.
FASEB JOURNAL (2008)
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
J. Qiao et al.
GENE THERAPY (2008)
Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy
Adam Vigil et al.
MOLECULAR THERAPY (2008)
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus
Timothy Kottke et al.
MOLECULAR THERAPY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2007)
Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells
L. Sanchez-Perez et al.
GENE THERAPY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
Rosa Maria Diaz et al.
CANCER RESEARCH (2007)
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion
Daniel J. Powell et al.
JOURNAL OF IMMUNOLOGY (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Giulia Fulci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals
E Ramsburg et al.
JOURNAL OF VIROLOGY (2005)
Engineering T cells for cancer therapy
W Mansoor et al.
BRITISH JOURNAL OF CANCER (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
EA Chiocca et al.
MOLECULAR THERAPY (2004)
Adoptive-cell-transfer therapy for the treatment of patients with cancer
ME Dudley et al.
NATURE REVIEWS CANCER (2003)
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
WW Overwijk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:: In vivo persistence, migration, and antitumor effect of transferred T cells
C Yee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going?
G Parmiani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
AL Pecora et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease
M Fernandez et al.
JOURNAL OF VIROLOGY (2002)
分享论文
